Brind.

Jazz Pharmaceuticals sued over LUMRYZ approval, which the FDA granted for narcolepsy treatment, leading to court rulings in the D.C. circuit.

2 reports, 1 independent Updated Jul 10

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Jazz Pharmaceuticals sued over LUMRYZ approval, which the FDA granted for narcolepsy treatment, leading to court rulings in the D.C. circuit.

Who's involved

What this event is mainly about

FDA Jazz Pharmaceuticals Avadel Pharmaceuticals

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
- Jazz Pharmaceuticals plans U.S. launch of Ziihera.Wed 22:28
- Alan M. Sebulsky was appointed to the Board of Directors of MeiraGTx Holdings PLC, where he has previously served.Wed 13:55
Avadel Pharmaceuticals
specialty pharmaceutical company

Nothing else this week.

Related events

Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.Aug 31

Coverage

Newest first; wire copies grouped

Jul 10Insider MonkeyAvadel Pharmaceuticals Receives Unanimous Appeals Court Affirmation for LUMRYZ FDA Approval Avadel Pharmaceuticals (NASDAQ:AVDL) is one of the most undervalued small-cap stocks to buy according to an
Jun 30Unknown outlet